Home » Stocks » Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. (EIGR)

Stock Price: $11.49 USD 0.21 (1.86%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $11.45 -0.04 (-0.35%) Aug 13, 5:48 PM

Stock Price Chart

Key Info

Market Cap 336.00M
Revenue (ttm) n/a
Net Income (ttm) -66.10M
Shares Out 25.06M
EPS (ttm) -2.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $11.49
Previous Close $11.28
Change ($) 0.21
Change (%) 1.86%
Day's Open 11.48
Day's Range 11.20 - 11.87
Day's Volume 701,071
52-Week Range 4.55 - 15.82

More Stats

Market Cap 336.00M
Enterprise Value 277.58M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.06M
Float 25.03M
EPS (basic) -2.66
EPS (diluted) -2.69
FCF / Share -2.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 689,974
Short Ratio 1.88
Short % of Float 3.08%
Beta 1.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.64
Revenue n/a
Operating Income -64.17M
Net Income -66.10M
Free Cash Flow -63.68M
Net Cash 58.43M
Net Cash / Share 2.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -33.45%
ROE -90.20%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$34.67*
(201.74% upside)
Low
23.0
Current: $11.49
High
56.0
Target: 34.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---------
Operating Income-68.90-51.05-41.52-46.12-12.97-1.52-19.96-15.95-6.03
Net Income-70.25-52.39-42.45-47.09-13.32-1.52-20.00-15.72-6.99
Shares Outstanding22.7913.638.736.010.210.190.060.05-
Earnings Per Share-3.08-3.84-4.86-7.84-62.19-7.82-406.41-295.95-40,924.44
Operating Cash Flow-63.61-42.67-38.37-37.97-9.13-1.28-16.20-14.64-5.61
Capital Expenditures-0.48-0.14-0.04-0.06-0.05--0.09-0.050.04
Free Cash Flow-64.09-42.81-38.42-38.03-9.18-1.28-16.28-14.69-5.58
Cash & Equivalents94.9910041.7859.944.7884.9518.3732.650.00
Total Debt32.2425.6215.0914.735.44-1.04--
Net Cash / Debt62.7574.7326.6945.21-0.6784.9517.3332.650.00
Assets10510242.8860.745.5889.1121.1535.93-
Liabilities48.6635.8620.3620.0210.7317.0172.1564.35-
Book Value56.4866.5922.5240.72-5.1572.10-50.99-28.42-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Eiger BioPharmaceuticals, Inc.
Country United States
Employees 28
CEO David A. Cory

Stock Information

Ticker Symbol EIGR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EIGR

Description

Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.